

RILSAN® FINE POWDERS D 50 NAT

RILSAN® fine powders are specialty polyamide powders obtained from renewable resources. RILSAN® D range is used as additive in paint formulations to provide excellent scratch and abrasion resistance and a desired structural effect in a wide range of liquid systems, both water-borne and solvent-borne.

<u>POWDER PROPERTIES</u>			
Nature	PA 11	ISO 1043	
Particle Size Distribution	Median size	40 - 46 µm	ISO 13320
Melting point	186 °C	ISO 1218	
Apparent Density (non compacted)	0.37	ISO 1068	
Ash Content	1 %	ISO 3451	
<u>COATING PROPERTIES</u>			
Specific gravity of the coating (20°C)	1.04	ISO 1183	
Water absorption @ 24 hrs	< 1 %	ISO 62/1	

RILSAN® FINE POWDERS D 50 NAT

MAIN APPLICATIONS

- Paint additive

PACKAGING

This grade is delivered in 20 kg bag.

SHELF LIFE

Five years from the date of delivery. For any use after this limit, please refer to our technical services.

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. Further, since the conditions and methods of use are beyond the control of ARKEMA, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.